In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tanox, Inc.

http://www.tanox.com

Latest From Tanox, Inc.

Ipsen In No Doubt About Its Abilities To Launch

Sales of the French firm’s new products missed consensus forecasts but CEO David Loew is confident that those drugs and the therapies that are close to the market will be commercial successes.

Sales & Earnings Business Strategies

ArriVent Is Second Positive IPO Of 2024 After CG Oncology’s Debut

ArriVent launched the second biopharma initial public offering of 2024, closing above its IPO price on its first day and grossing $175m – and keeping the financial market mood optimistic.

Financing Cancer

Asia Deal Watch: Argo Partners RNAi Programs With Novartis In Major Biobucks Pact

Plus deals involving Biocytogen/Radiance, Maruho/AOBiome, LGChem/Rhythm, IASO/Umoja, JW Therapeutics/2seventy and 13 other transactions.

Deal Watch Business Strategies

IPOs Fizzle Out In The Fourth Quarter

Just three biotech companies floated in the last three months of 2023, but there may be hope for a resurgence next year.

Financing Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register